Quick Answer
Lantern Pharma Inc. reported Diluted EPS of $1.57 per share (loss) for fiscal year 2025.
Lantern Pharma Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.57 | +18.7% |
| 2024 | -$1.93 | -31.3% |
| 2023 | -$1.47 | -12.2% |
| 2022 | -$1.31 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.39 | +7.1% | +2.5% |
| June 30, 2025 | -$0.40 | +13.0% | +4.8% |
| March 31, 2025 | -$0.42 | +17.6% | +0.0% |
| September 30, 2024 | -$0.42 | -44.8% | +8.7% |
| June 30, 2024 | -$0.46 | -4.5% | +9.8% |
| March 31, 2024 | -$0.51 | -41.7% | -75.9% |
| September 30, 2023 | -$0.29 | -38.1% | +34.1% |
| June 30, 2023 | -$0.44 | -7.3% | -22.2% |
- Lantern Pharma Inc. showed an increase of +18.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Lantern Pharma Inc.’s diluted eps has declined by 19.8% (from $1.31 per share (loss) to $1.57 per share (loss)).
- The most recent figure is from Lantern Pharma Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: